Next 10 |
2024-04-27 11:51:09 ET Nanobiotix S.A. (NBTX) Q4 2023 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Finan...
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial effi...
2024-04-23 08:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Bank of Hawaii Corporation (BOH) is expected to report $0.92 for Q1 2024 Brown & Brown Inc. (BRO) is expected to report $1.07 for Q1 2024 Independent Bank Group Inc (IBTX) is expected to report $0.57 for Q1 2024 Burnham Holdings Inc - Class A (BURCA) is expected to report for Q1 2...
PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapy Confirmation of injection feasibility and favorable safety profile in completed ...
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
2024-01-17 12:48:13 ET More on INVO BioScience Invo to acquire Naya Biosciences in all-stock deal Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience For further...
News, Short Squeeze, Breakout and More Instantly...
Nanobiotix S.A. Company Name:
NBTX Stock Symbol:
NASDAQ Market:
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial effi...
2024-04-23 08:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Bank of Hawaii Corporation (BOH) is expected to report $0.92 for Q1 2024 Brown & Brown Inc. (BRO) is expected to report $1.07 for Q1 2024 Independent Bank Group Inc (IBTX) is expected to report $0.57 for Q1 2024 Burnham Holdings Inc - Class A (BURCA) is expected to report for Q1 2...